Fig. 2
From: Real world study on efficacy and safety of surufatinib in advanced solid tumors evaluation
Based on the important factors of survival and progression-free survival of patients with neuroendocrine tumors treated with solvatinib. (A) Patients with a number of metastatic sites < 3 had longer OS than patients with a number of metastatic sites > 3. (B) Patients with an ECOG score of 0–1 had a longer OS than patients with an ECOG score of > 0–1. Patients with FFA > 635.5µmol/L had longer PFS than those with less than 3 OS(D) metastatic sites. OS, overall survival; PFS, progression-free; ECOG PS, Eastern Cooperative Oncology Group Performance status. FFA, free fatty acid.
